I[ntroduction]{.smallcaps} {#sec1-1}
==========================

The World Health Organization (WHO) comprehends diabetes mellitus as an emerging widespread epidemic disease. It is a general endocrine disorder impinging on greater than 150 million people worldwide and this number will probably multiply to 300 million by the year 2025.\[[@ref1][@ref2]\] Diabetes is recognized by augmented plasma glucose concentrations, due to inadequate insulin or insulin resistance, or together, as a result of metabolic abnormalities in carbohydrates, lipids, and proteins.\[[@ref3]\] Diabetes is characterized by hyperglycemia with modified lipid, carbohydrate, and protein metabolism, which influences the patient's state of life in all terms of social, psychological well-being, including physical ill health.\[[@ref4][@ref5]\] The WHO expressed that the people of Southeast Asia and Western Pacific fall under the category of higher risk, and the majority of these patients have type 2 diabetes. Insulin resistance is an indicator of the onset of type 2 diabetes and is frequently associated with several other cardiovascular risk factors such as dyslipidemia, hypertension, and prothrombotic factors.\[[@ref6]\] Diabetes-coupled with cardiovascular problems raises the risk due to the abnormal lipoprotein metabolism-mediated atherosclerosis, and patients with diabetes are two to four times more liable to experience stroke.\[[@ref7]\] Natural environment is a major resource for alternative medicines. The use of herbal medicine has been described in ancient literature, such as the Vedas and the Bible, which highlights the therapeutic potential of a wide range of wild plants. Plants produce a diverse group of bioactive molecules that serve as an affluent resource for several kinds of medicines.\[[@ref8][@ref9]\] Currently, the medicinal and nutraceutical herbs have garnered massive scientific consideration for their holistic effects.\[[@ref10][@ref11]\]

Since the existence, search for diabetes therapeutics and management has been relentless. It has propelled immense examinations attempting at identification as well as clinical trials of natural products obtained from plants and their analogs in drug discovery studies.\[[@ref12][@ref13][@ref14][@ref15][@ref16][@ref17]\]

However, no scientific records and reports were obtainable demonstrating the antidiabetic activity of *Litsea lancifolia* leaf extract in type 2 diabetes. The genus *Litsea* is one of the widest, distinct genera of evergreen shrubs that comprises approximately 400 species of shrubs. They are dispersed profusely all through tropical and subtropical Asia and North and South America. *Litsea* species have been used widely in traditional medicine for the treatment of several diseases including influenza, diarrhea, vomiting, stomach aches, diabetes, bone pain, inflammation, illness related to the central nervous system, and other ailments.\[[@ref18]\] The comprehensive and characterized reports in the ethnobotany, phytochemistry, and pharmacological research about the *Litsea* species enlighten us to explore their therapeutic potential and evaluate future research opportunities.\[[@ref18]\] [Figure 1](#F1){ref-type="fig"} shows an image of *L. lancifolia*, a Himalayan shrub.

![*Litsea lancifolia*: Himalayan evergreen shrub](JPBS-11-240-g001){#F1}

This study was aimed to investigate *in vitro* antidiabetic activity of the methanolic leaf extract of *L. lancifolia*, which was collected from thickets, streamsides, and forests, in 3T3L1 cell line model by performing assays such as glucose uptake activity, glucose transporter 4 (GLUT4) expression studies, and the inhibition of carbohydrate-metabolizing enzymes: pancreatic α-amylase and α-glucosidase.

M[aterials and]{.smallcaps} M[ethods]{.smallcaps} {#sec1-2}
=================================================

Chemicals and reagents {#sec2-1}
----------------------

The chemicals and reagents used in this study are as follows: Dulbecco's Modified Eagle's medium (DMEM) high glucose (\#AL219A, HiMedia, India), DMEM without glucose (\#AL186, HiMedia), adjustable multichannel pipettes and a pipettor (BenchTop Lab Systems, Saint Louis, Missouri, USA), fetal bovine serum (FBS) (\#RM10432, HiMedia), Dulbecco's phosphate-buffered saline (D-PBS) (\#TL1006, HiMedia), antibiotic solution (\#A018, HiMedia), 2-(*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) (\#13195, Invitrogen, USA), metformin (\#PHR1084, Sigma-Aldrich, USA), acarbose (\#A8980, Sigma-Aldrich), anti-mouse GLUT4--fluorescein isothiocyanate (FITC) antibody (\#NBPI-49533F, Novus Biologicals, USA), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reagent (\#4060, HiMedia), and dimethyl sulfoxide (DMSO) (\#PHR1309, Sigma-Aldrich).

Collection of plant material {#sec2-2}
----------------------------

Leaves of *L. lancifolia* were collected from Uttarakhand, India. The plant material was identified by Dr. Kotresha, Assistant Professor in Botany, East West College, Bengaluru, Karnataka, India. The collected leaves were washed thoroughly, shade dried, and then further processed.

Preparation of plant crude extract {#sec2-3}
----------------------------------

The leaves of *L. lancifolia* were air dried and minced into a powder by using mortar and pestle. Methanolic extract was prepared by using Soxhlet extraction method. Under reduced pressure, the solvent was evaporated using rotary evaporator (Buchi R-210, Marshall Scientific, USA). The dried extract was dissolved in DMSO at different concentrations and was used for *in vitro* antidiabetic assays.

Cell culture {#sec2-4}
------------

3T3L1 cell line was obtained from the National Centre for Cell Science (NCCS), Pune, Maharashtra, India, and cultured in DMEM (high glucose) supplemented with 10% FBS, 10,000 units of penicillin G, 10,000 μg/mL streptomycin sulfate, and 10mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) at 37°C in 5% CO~2~ atmosphere.

Cytotoxicity assay {#sec2-5}
------------------

The cytotoxicity of leaf extract of *L. lancifolia* was determined by MTT assay. The yellow-colored tetrazolium salt, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is converted to formazan crystals by the action of lactate dehydrogenase enzyme, produced by live cell mitochondria.\[[@ref19][@ref20]\] 3T3L1 cells at a density of 20 × 10^4^ cells per well/200 µL were seeded in a 96-well plate and cultured overnight. The spent medium was replaced with different concentrations of leaf extract (25--400 µg/mL) diluted in DMEM, and incubated for 24h at 5% CO~2~, and 37°C temperature. After 24h of incubation, the cells were treated with 0.5mg/mL of MTT reagent and incubated at 37°C temperature for 2h. Further, MTT reagent was removed and the formed formazan crystals were dissolved by adding 20 µL of DMSO. The purple-colored solution was measured at 570nm by microplate reader. The percentage of cell viability was calculated by considering the untreated cells as 100% viable population and using the following formula:

![](JPBS-11-240-g002.jpg)

Glucose uptake assay {#sec2-6}
--------------------

In a six-well plate, 3T3L1 cells were seeded at a density of 2 × 10^5^ cells/2mL and incubated in 5% CO~2~ overnight at 37°C. Later, the spent medium was removed and the cells were washed with D-PBS and treated with experimental compounds and controls in 2mL glucose-free culture medium containing 100 μM 2-NBDG and incubated for 2h. At the end of the treatment, medium was removed from all the wells and washed with D-PBS. Cells were harvested by trypsinization and washed with D-PBS, followed by centrifugation for 5min at 300 × *g* at 25°C. The supernatant was aspirated and the cells were resuspended in 0.5mL of D-PBS. FACSCalibur, BD Biosciences, USA was used to analyze the cellular uptake of 2-NBDG, by measuring fluorescence intensity in FL1 channel, and CellQuest Pro software, BD Biosciences, USA was used for data analysis.

Glucose transporter 4 expression studies {#sec2-7}
----------------------------------------

GLUT4 expression studies were performed by using flow cytometry technique. 3T3L1 cells were seeded in a six-well plate at a density of 2 × 10^5^ cells/2mL and incubated in an incubator (5% CO~2~) overnight at 37°C. The spent medium was aspirated and the cells were treated with 100 µg/mL of test compound showing 94.6% of cell viability in MTT assay and 100 µM of positive control, metformin. After 24h of the treatment, the spent medium was removed from all the wells and the cells were washed with D-PBS. The cells were harvested by trypsinization and were stained with anti-mouse GLUT4--FITC antibody (Novus Biologicals) for 30min in dark and the unbounded antibodies were washed with D-PBS. FACSCalibur was used to analyze the translocation of GLUT4 to cell membrane, by measuring fluorescence intensity in FL1 channel and CellQuest Pro software was used for data analysis.

Measurement of α-amylase activity {#sec2-8}
---------------------------------

Amylase activity was measured according to the standard protocol of Miller,\[[@ref21]\] by using dinitrosalicylic acid (DNSA) method and by using soluble starch as substrate. A total of 10% DMSO was used to prepare the desired stock concentration of leaf extract, and further dilutions were made using buffer (\[Na~2~HPO~4~/NaH~2~PO~4~, 0.02 M and NaCl, 0.006 M\] at pH 6.9) to get 31.25--500 μg/mL concentrations. Equal volumes of α-amylase solution (2 units/mL) and leaf extract (200 μL each) were mixed and incubated at 30°C for 10min. The reaction mixture was incubated with 200 μL of 1% starch solution for 3min. A total of 200 μL of DNSA reagent was added to the tubes and kept in boiling water bath for 10min at 85°C--90°C to terminate the reaction. After cooling the reaction mixture to room temperature, further dilutions were made by using distilled water and the absorbance was measured at 540nm using a microplate reader.

The wells with 200 μL of buffer alone served as blanks. Acarbose was used as positive control and 31.25--500 μg/mL of acarbose concentrations were prepared. The enzyme inhibition studies were performed similarly as aforementioned procedure. The percent inhibition of α-amylase was calculated using the equation given below. All the experiments were carried out in triplicates. A graph was plotted against the % inhibition of α-amylase and the concentration of leaf extract and acarbose, and the IC~50~ values were obtained from the graph.

![](JPBS-11-240-g003.jpg)

α-Glucosidase inhibition assay {#sec2-9}
------------------------------

The assay to analyze the α-glucosidase enzyme inhibitory activity of leaf extract was conducted based on the procedure previously described by Shibano *et al.*\[[@ref22]\] with minor modifications.

Test compounds at various concentrations from 31.25 to 500 μg/mL, prepared by using PBS (pH, 7.0), were mixed with 50 μL of 0.1 M phosphate buffer (pH, 7.0), 25 μL of 0.5mM 4-nitrophenyl α-[d]{.smallcaps}-glucopyranoside (dissolved in 0.1 M phosphate buffer with a pH of 7.0), and 25 μL of α-glucosidase solution (0.1 unit/mL), and then incubated for 30min at 37°C. Later, 100 μL of 0.2 M sodium carbonate solution was added to terminate the reactions. The quantity of *p*-nitrophenol liberated into the reaction mixture by the hydrolysis of the substrate was examined at 410nm using microplate reader. Wells with buffer alone were considered as blanks and were used to correct the background absorbance. Acarbose was used as positive control, and the leaf extract was taken in different concentrations ranging from 31.25 to 500 μg/mL. The percent inhibition of α-glucosidase was calculated using the equation given below. All the experiments were carried out in triplicates. A graph was plotted against the % inhibition of α-glucosidase and the concentration of leaf extract and acarbose, and the IC~50~ values were obtained from the graph.

![](JPBS-11-240-g004.jpg)

Statistical analysis {#sec2-10}
--------------------

IC~50~ value of percentage inhibition of enzymes was determined using linear regression graph (concentration vs. percentage enzyme inhibition). All the experiments were conducted in triplicates and the results were expressed as mean percentage inhibition ± standard deviation (SD) (n = 3). All statistical analyses and determination of IC~50~ values were carried out in GraphPad Prism (version 3.1) software (San Diego, CA).

R[esults]{.smallcaps} {#sec1-3}
=====================

Cytotoxicity effect of *Litsea lancifolia* on 3T3L1 cell line {#sec2-11}
-------------------------------------------------------------

The given test compound, *L. lancifolia* leaf extract, at varying concentrations (25--400 µg/mL) did not show cytotoxicity on 3T3L1 cells after the treatment for 24h. The concentrations of *L. lancifolia* leaf extract used to treat the 3T3L1 cells and the respective percentage of viability are given in [Table 1](#T1){ref-type="table"}. As metformin is a standard antidiabetic drug and has been used to conduct *in vitro* cell-based antidiabetic activities, the toxicity of metformin was also tested against 3T3L1 cells and it showed 91.52% of viability at 100 µM concentration. Untreated cells were considered as 100% viable cells. Each experiment was performed thrice and the results are represented as mean values ± SD \[[Table 1](#T1){ref-type="table"}\] \[Figures [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}\].

###### 

Cell viability effects of *Litsea lancifolia* extract in 3T3L1 cell line

  Culture conditions   Percentage of viability (%)
  -------------------- -----------------------------
  Control              100.00 ± 00
  25 μg/mL             97.71 ± 1.18
  50 μg/mL             96.37 ± 1.8
  100 μg/mL            94.36 ± 1.78
  200 μg/mL            91.95 ± 1.33
  400 μg/mL            90.81 ± 1.32
  Metformin (100 µM)   91.52 ± 1.58

![Effect of *Litsea lancifolia* leaf extract on 3T3L1 cell line viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay method and the test compound did not show high toxicity and IC~50~ could not be identified at given concentrations](JPBS-11-240-g005){#F2}

![Images of 3T3L1 cells taken by inverted light microscopy after the exposure to test compounds. From "A" to "C" where (A) condition medium, (B) standard metformin drug (100 µM), and (C) 400 µg/mL of *Litsea lancifolia* leaf extract treated cells for 24h.](JPBS-11-240-g006){#F3}

Inhibition of α-amylase activity {#sec2-12}
--------------------------------

*L. lancifolia* leaf extract showed 19.77% inhibition of α-amylase activity at 31.25 µg/mL and 73.29% at 500 µg/mL concentrations, respectively, and its IC~50~ value was found to be 248.65 µg/mL. The standard drug acarbose showed 34.16% inhibition of α-amylase activity at 31.25 µg/mL and 84.95% at 500 µg/mL concentrations, respectively, and its IC~50~ was found to be 47.54 µg/mL \[[Table 2](#T2){ref-type="table"}\] \[[Figure 4](#F4){ref-type="fig"}\].

###### 

Inhibition of α-amylase enzyme activity by *Litsea lancifolia* leaf extract

  Sample                        Concentration (μg/mL)   \% Inhibition of enzyme activity   IC~50~ (μg/mL)
  ----------------------------- ----------------------- ---------------------------------- ----------------
  Acarbose                      31.25                   34.16 ± 3.6                        47.54 ± 3.3
  62.50                         59.07 ± 1.7                                                
  125.00                        62.96 ± 2.6                                                
  250.00                        71.13 ± 1.7                                                
  500.00                        84.95 ± 0.18                                               
  *Litsea lancifolia* extract   31.25                   19.77 ± 4.38                       248.65 ± 8.7
  62.50                         29.38 ± 2.09                                               
  125.00                        45.76 ± 0.46                                               
  250.00                        52.98 ± 0.67                                               
  500.00                        73.29 ± 0.91                                               

![Inhibition percentage of α-amylase against different concentrations of acarbose and *Litsea lancifolia* leaf extract; the IC~50~ values of the acarbose and the extract are 47.54 and 248.65 µg/mL, respectively. Values are presented as mean ± standard deviation (SD)](JPBS-11-240-g007){#F4}

Inhibition of α-glucosidase activity {#sec2-13}
------------------------------------

*L. lancifolia* leaf extract showed 22.30% inhibition of α-glucosidase activity at 31.25 µg/mL and 74.51% at 500 µg/mL concentration, respectively, and its IC~50~ value was found to be 229.61 µg/mL. The standard drug, acarbose, showed 31.82% inhibitory effect on α-glucosidase activity at 31.25 µg/mL and 85.39% at 500 µg/mL concentrations, respectively, and its IC~50~ value was found to be 50.26 µg/mL \[[Table 3](#T3){ref-type="table"}\] \[[Figure 5](#F5){ref-type="fig"}\].

###### 

Inhibition of α-glucosidase enzyme activity by *Litsea lancifolia* leaf extract

  Sample                        Concentration (μg/mL)   \% Inhibition of enzyme activity   IC~50~ (μg/mL)
  ----------------------------- ----------------------- ---------------------------------- ----------------
  Acarbose                      31.25                   31.81 ± 1.09                       50.26 ± 9.57
  62.50                         57.62 ± 1.29                                               
  125.00                        66.02 ± 1.50                                               
  250.00                        73.24 ± 1.58                                               
  500.00                        85.39 ± 0.53                                               
  *Litsea lancifolia* extract   31.25                   22.30 ± 3.32                       229.61 ± 11.08
  62.50                         31.83 ± 4.55                                               
  125.00                        46.11 ± 0.1                                                
  250.00                        56.51 ± 1.66                                               
  500.00                        74.51 ± 1.82                                               

![Inhibition percentage of α-glucosidase at different concentrations of *Litsea lancifolia* leaf extract and acarbose. Values are presented as mean ± standard deviation (SD)](JPBS-11-240-g008){#F5}

Glucose transporter 4 expression study on 3T3L1 cell line by flow cytometry {#sec2-14}
---------------------------------------------------------------------------

The observation in statistical data of GLUT4 expression study by flow cytometry suggests that 0.12% of cells in untreated population, 99.67% cells in metformin (100 µM) treated population, and 86.26% of cells in *L. lancifolia* leaf extract--treated population showed GLUT4 expression. The results are shown in Figures [6](#F6){ref-type="fig"} and [7](#F7){ref-type="fig"}.

![Overlaid expression of glucose transporter 4 in untreated 3T3L1 cells (black color line) and standard drug--treated cells (metformin, 100 µM) (red color line) and 100 µg/mL of *Litsea lancifolia* leaf extract--treated cells (green color line)](JPBS-11-240-g009){#F6}

![Glucose transporter 4 (GLUT4) expression in untreated, 100 µM of metformin, and 100 µg/mL of *Litsea lancifolia* leaf extract treated cells for 24 h](JPBS-11-240-g010){#F7}

Glucose uptake assay {#sec2-15}
--------------------

Glucose uptake--inducing capabilities of the leaf extract was performed by treating 3T3L1 cells with 2-NBDG, a fluorescent deoxyglucose analog, in the presence and absence of test compounds. FACSCalibur was used to analyze the fluorescence intensity of 2-NBDG in FL1 channel. The overlaid fluorescence intensities of untreated cells, metformin, and leaf extract--treated cells are shown in [Figure 8](#F8){ref-type="fig"} and the percentage of cells with 2-NBDG uptake is shown in [Figure 9](#F9){ref-type="fig"}, respectively.

![Overlaid expression graph for the presence of fluorescent 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) in given untreated 3T3L1 cells (black color line) and standard drug--treated cells (metformin, 100µM) (red color line) and 100 µg/mL of *Litsea lancifolia* leaf extract--treated cells (green color line)](JPBS-11-240-g011){#F8}

![2-(*N*-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose (2-NBDG) expression in untreated, 100 µM of metformin-treated cells, and 100 µg/mL of *Litsea lancifolia* leaf extract--treated cells for 24 h](JPBS-11-240-g012){#F9}

D[iscussion]{.smallcaps} {#sec1-4}
========================

The controlling mechanisms of blood glucose varied based on the type of antidiabetic drug used. Mechanism of action of some drugs involves stimulation of insulin secretion or synthesis of insulin in adequate amounts by the pancreatic beta cells, regeneration of damaged pancreatic beta cells, increase of insulin sensitivity, which triggers glucose uptake by fat and muscle cells, impersonating the action of insulin, and finally, modification of the activity of some of the enzymes, especially related in glucose metabolism, and diminishing the absorption of sugars from the gut.\[[@ref23][@ref24]\] However, the usage of synthetic drugs for longer time span caused side effects, which led to the investigation and use of traditionally available natural plant species with no toxicity. *Litsea* is one among those naturally available plants shown to have promising, intense antidiabetic activity.

A preliminary cytotoxicity study was performed to analyze the cytotoxicity of *L. lancifolia* leaf extract against 3T3L1 cells by MTT assay. The results revealed that after 24h of incubation, the leaf extract did not show any toxicity. This screening of plants have been of great interest to scientists as plant extracts with no exhibited cytotoxicity may be useful in therapeutic applications.

Under regular conditions, glucose transport activity in muscle cells augments three- to fourfold pursing insulin stimulation, and a greater part of this outcome is related with a net translocation of the GLUT4 from intracellular compartment to the cell surface, where it makes it possible for the uptake and reduction of plasma glucose.\[[@ref25][@ref26][@ref27]\]

Experiments on cellular uptake of glucose revealed that *L. lancifolia* has the capability to induce glucose utilization by 3T3L1 cells. After incubation of cells with 100 μg/mL of *L. lancifolia* leaf extract for 2h at 37°C, 2-NBDG uptake was observed in 60.22% of cells, whereas it was observed in 99.94% of cells in the presence of 100 µM of the standard drug metformin. Moreover, these results can be correlated with GLUT4 expression studies, which showed the GLUT4 translocation--inducing capabilities of *L. lancifolia* leaf extract. 3T3L1 cells were treated with 100 μg/mL of *L. lancifolia* leaf extract and 100 µM of the standard drug metformin for 24h and were examined for the GLUT4 expression on the surface of cells by using flow cytometry. Both metformin and *L. lancifolia* leaf extract induced the translocation of GLUT4 in 99.67% and 86.26% of cells, respectively, after 24h of treatment. Thus, it indicates that cellular uptake of 2-NBDG might have occurred in 3T3L1 cells because of GLUT4 translocation--inducing capabilities of *L. lancifolia* leaf extract.

Carbohydrate-degrading digestive enzymes are considered to be one of the major targets in treating diabetic condition. These enzymes aid in the breakdown of complex carbohydrates of food and break them into smaller simple sugar units and increase their concentration in the bloodstream. Inhibition of these digestive enzymes can reduce the blood glucose levels in patients with diabetes mellitus.\[[@ref28]\] Thus, this study was envisioned to examine the inhibitory effect of *L. lancifolia* on the activity of these enzymes (i.e., α-amylase and α-glucosidase). Our results showed that methanolic leaf extract of *L. lancifolia* has a significant inhibitory effect on the activity of α-amylase enzyme and α-glucosidase enzyme with IC~50~ value of 248.65 µg/mL and 229.61 µg/mL, respectively. This inhibitory effect is comparable with the inhibitory effect of acarbose, which lowers the blood glucose levels in patients with diabetes.\[[@ref29][@ref30][@ref31][@ref32]\]

These observations and findings clearly proposed that the *L. lancifolia* leaf extract has possible therapeutic and antidiabetic properties. Voglibose, acarbose, and miglitol are examples of α-glucosidase and α-amylase inhibitors and are currently being used in clinical therapy.\[[@ref33]\] However, they are expensive and have a risk of clinical side effects such as abdominal distention, flatulence, meteorism, and diarrhea on long-term usage. Hence, use of natural resources such as *L. lancifolia* leaf extract, which show no toxicity can be recommended to diminish the hyperglycemic conditions with no side effects.

C[onclusion]{.smallcaps} {#sec1-5}
========================

The possible antidiabetic activity of methanolic leaf extract of *L. lancifolia* has been studied through *In vitro* studies. The experiments on glucose uptake and GLUT4 expression studies by flow cytometry in 3T3L1 cell line and colorimetric assays on α-amylase and α-glucosidase enzyme inhibition showed promising results when compared to that of the standard drugs metformin and acarbose, respectively. Moreover, methanolic extract of *L. lancifolia* leaf revealed no cytotoxicity against 3T3L1 cells, which concludes that *L. lancifolia* leaf extract could be recommended as a possible candidate for antidiabetic applications.

Summary {#sec2-16}
-------

-   The effect of *L. lancifolia* leaf extract was evaluated *in vitro* on 3T3L1 cell line.

-   We performed biochemical (α-amylase and α-glucosidase inhibition assays) and cellular assays (cellular glucose uptake and GLUT4 expression studies) to evaluate the antidiabetic activities of the extract.

-   *L. lancifolia* had no cytotoxic effect on 3T3L1 cells.

-   *L. lancifolia* extract showed significant inhibitory effect on the activity of α-amylase enzyme and α-glucosidase enzyme.

-   On treating 3T3L1 cells with *L. lancifolia* extract, 60.223% of the cells took up glucose and 86.263% expressed GLUT4.

-   *L. lancifolia* extract showed promising antidiabetic activity and could be a potential source of antidiabetic agents.
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